The Alzheimer's Network for Treatment and Diagnostics (ALZ-NET) is a collaborative effort to improve brain health outcomes, diagnosis and patient care. ALZ-NET connects clinical data from people living with Alzheimer's to our network of medical professionals and researchers to encourage information sharing and education, and to drive innovation in the ways we care for and treat Alzheimer's and all other dementia.
ALZ-NET features resources for clinicians and providers and is a platform for patients to access resources about Alzheimer's, including locating a medical expert in the network. Meanwhile, researchers will be able to advance the science behind future Alzheimer's and dementia treatments.
A word from Maria C. Carrillo, Ph.D., Chief Science Officer, Alzheimer's Association
"We are entering a new phase of Alzheimer's treatment. ALZ-NET is the tool that will help us translate emerging diagnostic tools and therapies into care that provides the most benefit to people living with the disease and their caregivers, in all communities. In collaboration with partners, medical professionals and scientific leaders, we are looking to develop the future of diagnosis, treatment and care by collecting and integrating data from real-world settings."
Why should medical professionals participate in
ALZ-NET provides medical professionals with access to real-world data, resources and instructions pertaining to ALZ-NET operations, dementia care resources, and imaging services for sites and clinicians.
What qualifications are needed to participate?
The Site Registration and Feasibility Survey will collect initial information from interested sites, including but not limited to:
- Access to accredited and appropriate radiological services for diagnostic and safety brain imaging.
- Access to infusion services.
- Access to emergency services.
- Access to standard cognitive, behavioral and functional assessments used in dementia care.
Information that describes the site's patient population and enrollment include but is not limited to:
- Estimated race and ethnicity of patient population.
- Estimated enrollment capabilities based on the ALZ-NET eligibility criteria.
Site investigator qualifications
- Must hold credentials that authorize prescription of novel FDA-approved therapies.
- Novel FDA-approved therapies for AD are drugs that have received approval as treatments for Alzheimer's disease (AD) from the U.S. Food and Drug Administration since 2021.
- Site investigator may be a physician, physician assistant, or nurse practitioner.
- All site investigators must have the appropriate education and ability for contact time for evaluation and care of adults with cognitive impairment or dementia.
How do medical professionals get started with ALZ-NET?
After reading the ALZ-NET Protocol Synopsis (PDF), qualified medical professionals and providers interested in joining ALZ-NET must submit the Site Registration and Feasibility Survey. If your site is invited to participate, you will receive instructions to continue the process.
Clinicians and specialists who participate in ALZ-NET will register their patients' experiences therapies, including safety and effectiveness.
For questions about timing and participation, or other inquiries about ALZ-NET, please contact email@example.com.
ALZ-NET provides training opportunities and resources to clinicians and participating sites.
ALZ-NET is sponsored by the Alzheimer's Association.
ALZ-NET is managed by the American College of Radiology.
Other partners include: